03 . 12 .2021
Press release
Galderma announces new data demonstrating the positive anti-inflammatory effect and mode of action of nemolizumab in patients with moderate to severe Prurigo Nodularis
29 . 11 .2021
Press release
Galderma to acquire award-winning ALASTIN Skincare® enhancing its integrated dermatology platform to continue delivering the best experience to patients
30 . 09 .2021
Press release
RESTYLANE®, the original stabilized hyaluronic acid filler, celebrates 25 years of unmatched achievement
29 . 09 .2021
Press release
Galderma presents new nemolizumab data at EADV reinforcing rapid onset of action and consistent relief of symptoms for people with prurigo nodularis and atopic dermatitis
28 . 09 .2021
Press release
Galderma to unveil ground-breaking data from across its leading dermatology portfolio and showcase major update for sensitive skincare brand CETAPHIL® at the 2021 EADV Congress
27 . 09 .2021
Press release
Galderma and CETAPHIL® Announce Renewed Commitment to Environmental Sustainability and Social Impact Through New Clear Skies Initiative
23 . 09 .2021
Press release
Galderma announces exclusive agreement with Sofregen to develop the next generation of biostimulator fillers using silk-based technology
09 . 09 .2021
Press release
Galderma to present new data from leading aesthetics portfolio and launch RESTYLANE® EYELIGHT™ at AMWC 2021
28 . 06 .2021
Press release
Sol-Gel Technologies and Galderma announce exclusive licenses for the commercialization of EPSOLAY® and TWYNEO® in the United States
11 . 06 .2021
Press release
Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe